Rezvilutamide plus docetaxel in chemotherapy‐naive metastatic castration‐resistant prostate cancer patients after progression on abiraterone: A multi‐centre, open‐label, phase II trial
Key Points
This trial aims to evaluate the effectiveness and safety of rezvilutamide combined with docetaxel in specific prostate cancer patients.
Multi-centre, open-label design
Inclusion of chemotherapy-naive, abiraterone-refractory mCRPC patients
Treatment with rezvilutamide plus docetaxel followed by rezvilutamide maintenance
Rezvilutamide plus docetaxel showed good tolerability
Promising efficacy observed in the targeted patient population
Abstract
Rezvilutamide plus docetaxel followed by maintenance with rezvilutamide monotherapy demonstrated good tolerability and promising efficacy in chemotherapy-naive, abiraterone-refractory, mCRPC patients.
Rezvilutamide plus docetaxel in chemotherapy‐naive metastatic castration‐resistant prostate cancer patients after progression on abiraterone: A multi‐centre, open‐label, phase II trial | Synapse